Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages E7788-E7797

  Hurton, Lenka V ^a,b   Singh, Harjeet ^a   Najjar, Amer M ^a   Switzer, Kirsten C ^a   Mi, Tiejuan ^a   Maiti, Sourindra ^a   Olivares, Simon ^a   Rabinovich, Brian ^a   Huls, Helen ^a,c   Forget, Marie Andrée ^a   Datar, Vrushali ^a   Kebriaei, Partow ^a   Lee, Dean A ^a   Champlin, Richard E ^a   Cooper, Laurence J N ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c INTREXON CORPORATION   (United States)

^d Ziopharm Oncology Inc   (United States)

Author keywords

Adoptive immunotherapy; CAR; IL 15; T cell persistence; T memory stem cell

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; FAS ANTIGEN; INTERLEUKIN 15; STAT5 PROTEIN; CD19 ANTIGEN, MOUSE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4 CD8 RATIO; CELL SPECIFICITY; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL; T LYMPHOCYTE SUBPOPULATION; T MEMORY STEM CELL; ANIMAL; EXPERIMENTAL NEOPLASM; HUMAN; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PRE T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD19; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS, EXPERIMENTAL; PRECURSOR CELLS, T-LYMPHOID; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84999293269     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1610544113     Document Type: Article

References (71)

1. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90(2):720-724.
2. Savoldo B, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822-1826.
3. Porter DL, et al. (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7 (303):303ra139.
4. Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: Building the ultimate antitumour T cell. Nat Rev Cancer 12(10):671-684.
5. Berger C, et al. (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118(1):294-305.
6. Hinrichs CS, et al. (2011) Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3):808-814.
7. Cieri N, et al. (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4):573-584.
8. Gattinoni L, et al. (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17(10):1290-1297.
9. Sabatino M, et al. (2016) Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128(4):519-528.
10. Lugli E, et al. (2013) Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 123(2):594-599.
11. Xu Y, et al. (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123(24):3750-3759.
12. Alwan LM, et al. (2014) Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol 9(1):63-71.
13. Matsuoka K, et al. (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5(179):179ra43.
14. Pipkin ME, et al. (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32(1):79-90.
15. Zhang X, Sun S, Hwang I, Tough DF, Sprent J (1998) Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8(5):591-599.
16. Marks-Konczalik J, et al. (2000) IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97(21):11445-11450.
17. Klebanoff CA, et al. (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101(7):1969-1974.
18. Teague RM, et al. (2006) Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12(3):335-341.
19. Mlecnik B, et al. (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6(228):228ra37.
20. Dadi S, et al. (2016) Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164(3):365-377.
21. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368.
22. Stoklasek TA, Schluns KS, Lefrançois L (2006) Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177(9):6072-6080.
23. Guo Y, et al. (2015) IL-15 superagonist-mediated immunotoxicity: Role of NK cells and IFN-γ. J Immunol 195(5):2353-2364.
24. Stonier SW, Ma LJ, Castillo EF, Schluns KS (2008) Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood 112(12):4546-4554.
25. Sato N, Patel HJ, Waldmann TA, Tagaya Y (2007) The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 104(2):588-593.
26. Kermer V, Baum V, Hornig N, Kontermann RE, Müller D (2012) An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 11(6):1279-1288.
27. Rhode PR, et al. (2016) Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res 4(1):49-60.
28. Singh H, et al. (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8(5):e64138.
29. Kebriaei P, et al. (2016) Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-3376.
30. Mortier E, et al. (2006) Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 281(3):1612-1619.
31. Rowley J, Monie A, Hung CF, Wu TC (2008) Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. J Immunol 181(12):8237-8247.
32. Zeng R, et al. (2005) Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 201(1):139-148.
33. Kaech SM, Cui W (2012) Transcriptional control of effector and memory CD8+ Tcell differentiation. Nat Rev Immunol 12(11):749-761.
34. Michie CA, McLean A, Alcock C, Beverley PC (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360(6401):264-265.
35. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708-712.
36. Jonnalagadda M, et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23(4):757-768.
37. Markley JC, Sadelain M (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115(17):3508-3519.
38. Kalos M, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73.
39. Robbins PF, et al. (2004) Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173(12):7125-7130.
40. Yee C, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ Tcellclonesfor the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168-16173.
41. Brentjens RJ, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38.
42. Kowolik CM, et al. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995-11004.
43. Maude SL, et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507-1517.
44. Lee DW, et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385(9967):517-528.
45. Park JH, et al. (2015) Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL. Blood 126(23):682.
46. Grange M, et al. (2012) Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res 72(1):76-87.
47. Hunter MR, et al. (2013) Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes. Mol Immunol 56(1-2):1-11.
48. Hoyos V, et al. (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6):1160-1170.
49. Ji Y, et al. (2015) miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci USA 112(2):476-481.
50. Conlon KC, et al. (2015) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33(1):74-82.
51. Kim EH, et al. (2012) Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol 188(9):4305-4314.
52. Grange M, et al. (2013) Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling. J Immunol 191(7):3712-3724.
53. Burchill MA, et al. (2003) Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: Development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol 171(11):5853-5864.
54. Long AH, et al. (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581-590.
55. Hasan AN, et al. (2016) Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8(+) T cells for adoptive immunotherapy of cancer and infections. Clin Exp Immunol 186(2):249-265.
56. Castro I, Yu A, Dee MJ, Malek TR (2011) The basis of distinctive IL-2- and IL-15-dependent signaling: Weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development. J Immunol 187(10):5170-5182.
57. Geginat J, Lanzavecchia A, Sallusto F (2003) Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101(11):4260-4266.
58. Wu D, Pan W (2010) GSK3: A multifaceted kinase in Wnt signaling. Trends Biochem Sci 35(3):161-168.
59. van der Waart AB, et al. (2014) Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 124(23):3490-3500.
60. Boyman O, Krieg C, Homann D, Sprent J (2012) Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci 69(10):1597-1608.
61. Klebanoff CA, et al. (2015) Klebanoff CA, et al. (2016) Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest 126(1):318-334.
62. Mishra A, et al. (2012) Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22(5):645-655.
63. Mishra A, et al. (2016) Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov 6(9):986-1005.
64. Fehniger TA, et al. (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 193(2):219-231.
65. Sato N, et al. (2011) Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα. Blood 117(15):4032-4040.
66. Imamura M, et al. (2014) Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124(7):1081-1088.
67. Hsu C, et al. (2007) Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109(12):5168-5177.
68. Denman CJ, et al. (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264.
69. Singh H, et al. (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71(10):3516-3527.
70. Cooper LJ, et al. (2003) T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101(4):1637-1644.
71. Singh H, et al. (2007) Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res 67(6):2872-2880.